Navigation Links
Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain

New Analysis Examines Impact of Pain on Sleep Interference

INDIANAPOLIS, May 03, 2007 /PRNewswire-FirstCall/ -- Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill. Results from the analysis of more than 1,000 patients were presented today at the annual meeting of the American Pain Society in Washington D.C.

The average daily night pain severity and sleep interference correlation assessments were secondary analyses of data from trials in which the primary efficacy endpoint was to measure the reduction in average weekly pain. For these assessments, a subset of nonsomnolent patients was created by removing those who experienced treatment-related somnolence (such as daytime sleepiness, drowsiness, grogginess or difficulty awakening) or who were on other sedating medications. At the end of the 12-week analysis, this subset of patients treated with 60 mg of Cymbalta once- and twice-daily experienced significantly more improvement in 24-hour average pain scores than those taking sugar pill (47 percent, 50 percent and 29 percent respectively), as measured by reduction of scores on the self-reported, 11-point Likert scale.

In analyses of the effect of Cymbalta on night pain and pain-related sleep interference, nonsomnolent/nonsedating drug patients treated with 60 mg of Cymbalta once- and twice-daily experienced significantly more improvement in nighttime pain than those taking sugar pill after one week of treatment (22 percent, 21 percent and 10 percent, respectively) and at the end of the 12 weeks (47 percent, 51 percent compared with 34 percent). Both doses of Cymbalta reduced pain-related sleep inter
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
9. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
10. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
11. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
Post Your Comments:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, ... will host its Second Quarter 2015 Investor Conference Call ...    The call will cover an update ... second quarter 2015 financials. A press release detailing the ... issued the afternoon of Monday, August 10. Investors and ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... Northwestern Memorial Hospital is one of six national participants ... lung cancer patients and their families have a smoother ... to reduce medical error and to reliably adhere to ... Commission on Cancer and the Society of Thoracic Surgeons ...
... PRUSSIA, Pa., Nov. 18, 2010  Prism ... & Drug Administration (FDA) has approved the supplemental ... Injection, the first and only premixed intravenous (IV) ...  NEXTERONE Premixed Injection is indicated for initiation of ...
Cached Medicine Technology:Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 2Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 3
(Date:8/3/2015)... ... , ... They know every second counts. And when it comes to stroke, ... the best care in the nation. For the past two months, the stroke team ... removal time in the country. During the months of June and July, it took ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... and fitness site and the largest online retailer of nutritional supplements, has ... Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2
... tips on controlling your flatulence , ... East Longmeadow, ... necessary. In fact, the average person passes gas about 14 times ... However, every body behaves differently and some experience more gas than ...
... Robert Bernstein, developer of the Follicular Unit Transplantation procedure for ... hair loss and its treatment. , ... ... The Oprah Winfrey Show features Dr. Bernstein discussing his pioneering ...
... previously published ACSM/AHA, guidelines, INDIANAPOLIS ... activity released today by the U.S. Department ... with support from the American College of,Sports ... (AHA). The,organizations, which jointly published physical activity ...
... ANAHEIM, Calif., Oct. 7 CHADD, ... by AD/HD, will hold its Annual,International ... Anaheim, California.,The conference will feature some ... variety,topics of interest to parents, adults, ...
... similar to more expensive whole-leg color ultrasound, study ... older, simpler test to look for blood clots in ... -- is as effective as a newer, more expensive ... 2-point ultrasonography of the leg -- sometimes called compression ...
... the University of California, San Diego (UCSD) in La Jolla ... lung cancer by treating patients with a novel kind of ... immune system to fight off a cancer, the new vaccine, ... turning off its immune system-suppressing activities. , The first patients ...
Cached Medicine News:Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... AccuGENE Molecular Biology Buffers are ready-to-use ... molecular biology applications. Each reagent is prepared ... 0.2 micron filter, and filled into sterile ... strict quality control standards to ensure lot-to-lot ...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
Medicine Products: